Cognitive Function News and Research

RSS

Cognition is a concept used in different ways by different disciplines, but is generally accepted to mean the process of thought. For example, in psychology and cognitive science it refers to an information processing view of an individual's psychological functions.

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

HeartWare's ADVANCE bridge-to-transplant clinical trial: FDA approves additional enrollment under CAP

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration has approved an IDE Supplement that allows HeartWare to enroll up to an additional 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).

8 Apr 2010

Entry to aged-care facilities largely preventable

Lifestyle, social and health factors, such as being underweight, having inadequate nutrition or having low social activity, have been shown to be significant contributing factors to the entry of older people into residential aged care.

8 Apr 2010

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

A natural products chemistry company has licensed the rights for a promising botanical compound from the University of Mississippi and the Agricultural Research Service, which is the principal intramural scientific research agency of the U.S. Department of Agriculture.

2 Apr 2010

BELLUS Health initiates Phase I clinical study for NRM8499

BELLUS Health Inc. announced today that, on March 30, 2010, the Company initiated a Phase I clinical study for NRM8499, a prodrug of tramiprosate. NRM8499 is intended for the treatment of Alzheimer's disease.

1 Apr 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

New, portable EEG-based device for people with motoric disabilities

Imec, Holst Centre and the lab of Neuro- and Psychophysiology at the Katholieke Universiteit Leuven today present the Mind Speller, a portable, easy-to-wear, intelligent textual and verbal communications prototype device enabling people with motoric disabilities (suffering from for example brain paralysis or speech or language disorders) to communicate.

24 Mar 2010

New software may help improve safety among senior drivers

Psychologists at the University of Alabama at Birmingham (UAB) Center for Research in Applied Gerontology are testing software to determine if it could help senior adult drivers avoid car crashes by improving their reflexes and reaction time

24 Mar 2010

Role of structured physical activity in preventing or delaying mobility disabilities in older adults

Wake Forest University Baptist Medical Center, together with Wake Forest University, will play a key role in a new study that seeks to determine whether a program of structured physical activity can prevent or delay major mobility disabilities in older adults.

19 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

CogniFit Personal Coach brain training software improves cognitive function of MS patients

CogniFit™, Inc., a leading maker of Brain Fitness Software (www.cognifit.com), announced a new, independent study that shows CogniFit Personal Coach brain training software improves the cognitive function and skills of Multiple Sclerosis (MS) patients.

16 Mar 2010

Long-term tobacco dependence may affect memory and thinking in women

Men and women with a history of alcohol abuse may not see long-term negative effects on their memory and thinking, but female smokers do, a new study suggests.

16 Mar 2010

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Rhesus monkey babies born to mothers who had the flu while pregnant had smaller brains and showed other brain changes similar to those observed in human patients with schizophrenia, a study at the University of Wisconsin-Madison in collaboration with the University of North Carolina at Chapel Hill has found.

12 Mar 2010

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

11 Mar 2010

Augmentation with ketone bodies improves cognitive function in AD patients

Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients.

10 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

The Research Partnership in Cognitive Aging, a public-private effort to promote the study of brain function with age, will award up to $28 million over five years to 17 research grants to examine the neural and behavioral profiles of healthy cognitive aging and explore interventions that may prevent, reduce or reverse cognitive decline in older people.

2 Mar 2010

Chronic stroke impairment: Intensive, repetitive rehabilitation exercises may benefit arms, legs and cognitive function

High-intensity, repetitive rehabilitation exercises can help stroke survivors significantly improve functioning in their paralyzed arm and in their quality of life — even years after their disabling event, according to late-breaking science results presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Cognitive Function News and Research

Further Reading

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Role of beta defensins in development of chronic inflammatory response in the brain

HeartWare's ADVANCE bridge-to-transplant clinical trial: FDA approves additional enrollment under CAP

Entry to aged-care facilities largely preventable

Researchers commence Phase 2 research study to test CERE-110 for AD

ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

BELLUS Health initiates Phase I clinical study for NRM8499

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

New, portable EEG-based device for people with motoric disabilities

New software may help improve safety among senior drivers

Role of structured physical activity in preventing or delaying mobility disabilities in older adults

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

CogniFit Personal Coach brain training software improves cognitive function of MS patients

Long-term tobacco dependence may affect memory and thinking in women

Flu infection during pregnancy may increase risk of schizophrenia in offspring

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

Augmentation with ketone bodies improves cognitive function in AD patients

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

Chronic stroke impairment: Intensive, repetitive rehabilitation exercises may benefit arms, legs and cognitive function

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News